Oncology PracticeCommunity practice lung cancer patients insufficiently tested for treatment-related biomarkersJune 6, 2021Lung CancerASCO Lung Cancer
Oncology PracticeNSCLC: Immune-related AEs during checkpoint inhibitor therapy may predict outcomesJune 6, 2021Lung CancerASCO Lung Cancer
Oncology PracticeImmunotherapy takes first major step into earlier NSCLCMay 24, 2021Lung CancerASCO Lung Cancer
Oncology PracticeImmunotherapy combo improves ORR, PFS in PD-L1+ NSCLCJune 22, 2020Lung CancerASCO Lung Cancer
Oncology PracticeCheckMate 9LA: ‘Doing better’ for stage IV/recurrent NSCLCJune 18, 2020Lung CancerASCO Lung Cancer
Oncology Practice‘Hospital at home’ cuts ED visits and costs for cancer patientsJune 12, 2020Patient & Survivor CareGastroenterologyGynecologic CancerGenitourinary CancerLung CancerASCO Lung CancerGastrointestinal Cancer
Oncology PracticeNo OS benefit with gefitinib vs. chemo for EGFR+ NSCLCJune 10, 2020Lung CancerASCO Lung Cancer
Oncology PracticeTepotinib elicits responses in METex14 NSCLCJune 10, 2020Lung CancerASCO Lung Cancer
Oncology PracticeTKI plus SBRT tops TKI alone for oligometastatic EGFRm NSCLCJune 8, 2020Lung CancerASCO Lung Cancer
Oncology PracticePembrolizumab plus EP gives slight PFS edge in ES-SCLCJune 5, 2020Lung CancerASCO Lung Cancer
Oncology Practice‘Promising’ durvalumab results spark phase 3 trial in mesotheliomaJune 4, 2020Lung CancerASCO Lung Cancer
Oncology PracticeGermline testing in advanced cancer can lead to targeted treatmentJune 3, 2020Mixed TopicsBreast CancerCNS/Brain CancerGastroenterologyGenitourinary CancerGynecologic CancerHead & Neck/Thyroid Cancers
Oncology PracticeTrastuzumab deruxtecan proves active in HER2-mutated NSCLCMay 31, 2020Lung CancerASCO Lung Cancer
Oncology PracticeFirst-line nivolumab plus platinum/etoposide effective in extensive-stage SCLCMay 30, 2020Lung CancerASCO Lung Cancer
